Clopenthixol is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Clopenthixol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clopenthixol. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Clopenthixol. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Clopenthixol. |
| Hydrocodone | Clopenthixol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clopenthixol. |
| Magnesium sulfate | The therapeutic efficacy of Clopenthixol can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Clopenthixol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Clopenthixol may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Clopenthixol. |
| Mirtazapine | Clopenthixol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Clopenthixol. |
| Orphenadrine | Clopenthixol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Clopenthixol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Clopenthixol. |
| Rotigotine | Clopenthixol may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Clopenthixol. |
| Sodium oxybate | Clopenthixol may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Clopenthixol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Clopenthixol. |
| Thalidomide | Clopenthixol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Clopenthixol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Amisulpride | Clopenthixol may increase the antipsychotic activities of Amisulpride. |
| Methylphenidate | The risk or severity of adverse effects can be increased when Clopenthixol is combined with Methylphenidate. |
| Dexmethylphenidate | The risk or severity of adverse effects can be increased when Clopenthixol is combined with Dexmethylphenidate. |
| Metoclopramide | The risk or severity of adverse effects can be increased when Metoclopramide is combined with Clopenthixol. |
| Quinagolide | The therapeutic efficacy of Quinagolide can be decreased when used in combination with Clopenthixol. |
| Sulpiride | Clopenthixol may increase the antipsychotic activities of Sulpiride. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Clopenthixol. |
| Lithium citrate | Lithium citrate may increase the neurotoxic activities of Clopenthixol. |
| Lithium hydroxide | Lithium hydroxide may increase the neurotoxic activities of Clopenthixol. |
| Mequitazine | Clopenthixol may increase the arrhythmogenic activities of Mequitazine. |
| Ethanol | Clopenthixol may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Clopenthixol may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Clopenthixol. |
| Zimelidine | The risk or severity of adverse effects can be increased when Clopenthixol is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Clopenthixol is combined with Dapoxetine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Clopenthixol is combined with Seproxetine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Clopenthixol is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Clopenthixol is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Clopenthixol is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Clopenthixol is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Clopenthixol is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Clopenthixol is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Clopenthixol is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Clopenthixol is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Clopenthixol is combined with Escitalopram. |
| Milnacipran | The risk or severity of adverse effects can be increased when Clopenthixol is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Clopenthixol is combined with Desvenlafaxine. |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Clopenthixol. |
| Indalpine | The risk or severity of adverse effects can be increased when Clopenthixol is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Clopenthixol is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Clopenthixol is combined with Alaproclate. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Clopenthixol. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with Clopenthixol. |
| Zopiclone | The risk or severity of adverse effects can be increased when Clopenthixol is combined with Zopiclone. |
| Eletriptan | The risk or severity of adverse effects can be increased when Eletriptan is combined with Clopenthixol. |
| Cabergoline | The risk or severity of adverse effects can be increased when Cabergoline is combined with Clopenthixol. |
| Zolmitriptan | The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Clopenthixol. |
| Meperidine | The risk or severity of adverse effects can be increased when Meperidine is combined with Clopenthixol. |
| Dextromethorphan | The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Clopenthixol. |
| Mazindol | The risk or severity of adverse effects can be increased when Mazindol is combined with Clopenthixol. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Clopenthixol. |
| Sumatriptan | The risk or severity of adverse effects can be increased when Sumatriptan is combined with Clopenthixol. |
| Ergotamine | The risk or severity of adverse effects can be increased when Ergotamine is combined with Clopenthixol. |
| Fentanyl | The risk or severity of adverse effects can be increased when Fentanyl is combined with Clopenthixol. |
| Almotriptan | The risk or severity of adverse effects can be increased when Almotriptan is combined with Clopenthixol. |
| Naratriptan | The risk or severity of adverse effects can be increased when Naratriptan is combined with Clopenthixol. |
| Rizatriptan | The risk or severity of adverse effects can be increased when Rizatriptan is combined with Clopenthixol. |
| Frovatriptan | The risk or severity of adverse effects can be increased when Frovatriptan is combined with Clopenthixol. |
| Chlorpheniramine | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Clopenthixol. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Clopenthixol. |
| Bromocriptine | The risk or severity of adverse effects can be increased when Bromocriptine is combined with Clopenthixol. |
| Ergometrine | The risk or severity of adverse effects can be increased when Ergometrine is combined with Clopenthixol. |
| Rasagiline | The risk or severity of adverse effects can be increased when Rasagiline is combined with Clopenthixol. |
| Lorcaserin | The risk or severity of adverse effects can be increased when Lorcaserin is combined with Clopenthixol. |
| Etoperidone | The risk or severity of adverse effects can be increased when Etoperidone is combined with Clopenthixol. |
| Lorpiprazole | The risk or severity of adverse effects can be increased when Lorpiprazole is combined with Clopenthixol. |
| Amphetamine | Clopenthixol may decrease the stimulatory activities of Amphetamine. |
| Phentermine | Clopenthixol may decrease the stimulatory activities of Phentermine. |
| Pseudoephedrine | Clopenthixol may decrease the stimulatory activities of Pseudoephedrine. |
| Benzphetamine | Clopenthixol may decrease the stimulatory activities of Benzphetamine. |
| Diethylpropion | Clopenthixol may decrease the stimulatory activities of Diethylpropion. |
| Lisdexamfetamine | Clopenthixol may decrease the stimulatory activities of Lisdexamfetamine. |
| Mephentermine | Clopenthixol may decrease the stimulatory activities of Mephentermine. |
| MMDA | Clopenthixol may decrease the stimulatory activities of MMDA. |
| 2,5-Dimethoxy-4-ethylamphetamine | Clopenthixol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine. |
| Chlorphentermine | Clopenthixol may decrease the stimulatory activities of Chlorphentermine. |
| Methylenedioxyethamphetamine | Clopenthixol may decrease the stimulatory activities of Methylenedioxyethamphetamine. |
| Dextroamphetamine | Clopenthixol may decrease the stimulatory activities of Dextroamphetamine. |
| Metamfetamine | Clopenthixol may decrease the stimulatory activities of Metamfetamine. |
| Iofetamine I-123 | Clopenthixol may decrease the stimulatory activities of Iofetamine I-123. |
| Ritobegron | Clopenthixol may decrease the stimulatory activities of Ritobegron. |
| Mephedrone | Clopenthixol may decrease the stimulatory activities of Mephedrone. |
| Methoxyphenamine | Clopenthixol may decrease the stimulatory activities of Methoxyphenamine. |
| Gepefrine | Clopenthixol may decrease the stimulatory activities of Gepefrine. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | Clopenthixol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine. |
| Phendimetrazine | Clopenthixol may decrease the stimulatory activities of Phendimetrazine. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Clopenthixol. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Clopenthixol. |